@article{e03581096f134ecd99b90e2521732ffb,
title = "Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study",
keywords = "anticoagulants, haemorrhage, off-label use, clinical trial, phase IV, stroke, thromboembolism",
author = "{de Vries}, {Tim A. C.} and Hemels, {Martin E. W.} and Frank Cools and Crijns, {Harry J. G. M.} and Laetitia Yperzeele and Peter Vanacker and Ivan Blankoff and Patrizio Lancellotti and Mairesse, {Georges H.} and {de Veer}, Anne and {Casado Arroyo}, Ruben and Emmanuel Catez and {de Pauw}, Michel and Thomas Vanassche and {de Asmundis}, Carlo and Paulus Kirchhof and {De Caterina}, Raffaele and {de Groot}, {Joris R.} and {ETNA-AF-Europe principal investigators from Belgium and the Netherlands}",
year = "2021",
month = jul,
day = "4",
doi = "10.1080/00015385.2020.1746095",
language = "English",
volume = "76",
pages = "431--439",
journal = "Acta Cardiologica",
issn = "0001-5385",
publisher = "Routledge/Taylor & Francis Group",
number = "4",
}